“Cryptic Promoters” Drive Stomach Cancer
Using a new technique called Nano-ChIPseq, scientists have found that stomach cancer is driven by mutations in regions of the genome known... Read More
New Provider Resources for Improving Gastric Cancer Patient Care
The Association of Community Cancer Centers Announces New Provider Resources for ImprovingGastric Cancer Patient Care/p> ACCC Names Four Cancer Centers as Community... Read More
Gastric Cancer Detected in a Breath Test
By detecting certain volatile organic compounds in exhaled breath, NanoArtificial Nose technology (NA-NOSE) was able to differentiate patients with gastric cancer from... Read More
Eradicating H pylori Could Help Prevent Gastric Cancer in Asians
Searching for and eradicating the bacteria Helicobacter pylori could reduce the incidence of gastric cancer in otherwise healthy individuals, especially in Asian... Read More
ASCO: Advances in the Management of Gastrointestinal Cancers
As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3 in Chicago,... Read More
FDA approves Cyramza for stomach cancer
The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a... Read More
Long noncoding RNA in gastric juice, plasma may be marker for gastric cancer
Changes in long noncoding RNA-AA174084 levels in the tissues, gastric juice and plasma of patients with gastric cancer were associated with clinicopathological... Read More
Could the Microbiome Play a Role in Gastric Cancer?
Over the past few years, the scientific community has become more and more interested in the “microbiome”-the 100 trillion or so bacteria... Read More
Researchers Identify Early Signs of Gastric Cancer
It has long been known that Helicobacter pylori infection can be a risk factor for gastric cancer, but what’s not known is... Read More
Lilly Announces Second Positive Phase III Gastric Cancer Study
INDIANAPOLIS, Sept. 26, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced top-line results from two global Phase III studies... Read More